Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan [PDF]
Cancer MedicineBackground Members of the neurotrophic tropomyosin receptor kinase (NTRK) gene family, NTRK1, NTRK2, and NTRK3 encode TRK receptor tyrosine kinases. Intra‐ or inter‐chromosomal gene rearrangements produce NTRK gene fusions encoding fusion proteins which ...
Eiji Nakata +5 more
doaj +3 more sources
ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models [PDF]
Cell ReportsSummary: Pediatric-type high-grade gliomas frequently harbor gene fusions involving receptor tyrosine kinase genes, including neurotrophic tyrosine kinase receptor (NTRK) fusions.
Sebastian Schmid +17 more
doaj +4 more sources
NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphoma [PDF]
Frontiers in Oncology, 2023 BackgroundEven though two NTRK-targeting drugs are available for the treatment of irresectable, metastatic, or progressive NTRK-positive solid tumors, less is known about the role of NTRK fusions in lymphoma.
Susanne Ghandili +4 more
doaj +2 more sources
Clinicopathological and sonographic characterization of NTRK-fusion papillary thyroid carcinoma based on preoperative molecular testing: a comparative study with BRAFV600E PTC [PDF]
Frontiers in OncologyBackgroundNTRK fusions are relatively rare in papillary thyroid carcinoma (PTC), and their clinicopathological characteristics, particularly in unselected populations and in comparison with BRAFV600E PTC, have not been systematically elucidated.MethodsIn
Yuzhi Zhang +9 more
doaj +2 more sources
NTRK fusion promotes tumor migration and invasion through epithelial–mesenchymal transition and closely interacts with ECM1 and NOVA1 [PDF]
BMC CancerBackground The NTRK fusion gene is a rare cancer driver and a typical representative "diamond mutation". Its unique role in tumor progression is highly important for the clinical diagnosis and treatment of patients with tumors.
Siqing Zeng +7 more
doaj +2 more sources
Evaluation of NTRK Gene Fusion by Five Different Platforms in Triple-Negative Breast Carcinoma
Frontiers in Molecular Biosciences, 2021 Triple-negative breast carcinoma (TNBC) is an aggressive disease that has a poor prognosis since it lacks effective treatment methods. Neurotrophic tyrosine receptor kinase (NTRK) fusion genes are excellent candidates for targeted RTK inhibitor therapies
Shafei Wu +5 more
doaj +3 more sources
NTRK fusion in Japanese colorectal adenocarcinomas [PDF]
Scientific Reports, 2021 NTRK fusion-positive tumors are known to be highly sensitive to TRK inhibitors, such as larotrectinib and entrectinib. Therefore, identification of patients who can potentially benefit from these inhibitors is important; however, the frequency of NTRK ...
Yuya Yamashiro +6 more
doaj +2 more sources
KIT Mutation-NTRK fusion oncogenic driver switch: a novel mechanism of acquired imatinib resistance in GIST [PDF]
npj Precision OncologyImatinib is the first-line treatment for advanced gastrointestinal stromal tumors (GISTs) harboring KIT or PDGFRA mutations. Unfortunately, resistance invariably develops, typically through secondary KIT/PDGFRA mutations.
Simona Gloazzo +12 more
doaj +2 more sources
Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers [PDF]
European Thyroid JournalContext: Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have radioiodine (RAI)-resistant disease, resulting in poor prognosis and high mortality.
Abdul Rehman Syed +9 more
doaj +2 more sources
NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer [PDF]
Journal of Cancer Research and Clinical Oncology, 2023 Matthias Kroiss +2 more
exaly +2 more sources